These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9636844)

  • 1. Combination immunotherapy and antifungal chemotherapy.
    Stevens DA
    Clin Infect Dis; 1998 Jun; 26(6):1266-9. PubMed ID: 9636844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in patients with systemic mycoses: a promising adjunct.
    Farmaki E; Roilides E
    BioDrugs; 2001; 15(4):207-14. PubMed ID: 11437686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia.
    Dignani MC; Rex JH; Chan KW; Dow G; deMagalhaes-Silverman M; Maddox A; Walsh T; Anaissie E
    Cancer; 2005 Jul; 104(1):199-204. PubMed ID: 15929126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment: antifungal drugs with antibodies, cytokines or drugs.
    Stevens DA; Kullberg BJ; Brummer E; Casadevall A; Netea MG; Sugar AM
    Med Mycol; 2000; 38 Suppl 1():305-15. PubMed ID: 11204158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections.
    Safdar A
    Clin Microbiol Infect; 2007 Jan; 13(1):1-4. PubMed ID: 17184281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cases illustrating successful adjunctive interferon-γ immunotherapy in refractory disseminated coccidioidomycosis.
    Duplessis CA; Tilley D; Bavaro M; Hale B; Holland SM
    J Infect; 2011 Sep; 63(3):223-8. PubMed ID: 21791226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy.
    Roilides E; Farmaki E
    Clin Microbiol Infect; 2001; 7 Suppl 2():62-7. PubMed ID: 11525220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium.
    Böhme A; Karthaus M
    Chemotherapy; 1999; 45(5):315-24. PubMed ID: 10473919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients.
    Armstrong-James D; Teo IA; Shrivastava S; Petrou MA; Taube D; Dorling A; Shaunak S
    Am J Transplant; 2010 Aug; 10(8):1796-803. PubMed ID: 20353472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host immune reactivity and antifungal chemotherapy: the power of being together.
    Romani L
    J Chemother; 2001 Aug; 13(4):347-53. PubMed ID: 11589476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.
    Rodríguez MM; Calvo E; Mariné M; Pastor FJ; Fernandez-Ballart J; Guarro J
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3569-71. PubMed ID: 19451289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.
    Cenci E; Mencacci A; Del Sero G; Fé d'Ostiani C; Montagnoli C; Bacci A; Bistoni F; Romani L
    J Chemother; 1998 Apr; 10(2):160-3. PubMed ID: 9603646
    [No Abstract]   [Full Text] [Related]  

  • 14. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
    Feili-Hariri M; Falkner DH; Morel PA
    J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Future directions of antimycotic therapy].
    Meunier F
    Mycoses; 1994; 37 Suppl 2():77-82. PubMed ID: 7541893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The immune response to fungal infections].
    Kurnatowski P; Kurnatowska AJ
    Wiad Parazytol; 2010; 56(1):23-7. PubMed ID: 20450005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends in antifungal therapy: focus on systemic mycoses.
    Ray A; Anand S
    Indian J Chest Dis Allied Sci; 2000; 42(4):357-66. PubMed ID: 15597685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.
    Mencacci A; Cenci E; Bacci A; Bistoni F; Romani L
    J Infect Dis; 2000 Feb; 181(2):686-94. PubMed ID: 10669356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches to antifungal chemotherapy.
    Viviani MA; de Marie S; Graybill JR; Yamaguchi H; Anaissie E; Caillot D
    Med Mycol; 1998; 36 Suppl 1():194-206. PubMed ID: 9988508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for monocyte-mediated immunotherapy during infection and malignancy--Part II: in vivo activation by exogenous cytokines and clinical applications.
    Williams MA; Rhoades CJ; Newland AC; Kelsey SM
    Leuk Lymphoma; 1999 Jul; 34(3-4):207-30. PubMed ID: 10439359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.